The Use of Zoledronic Acid in Men on Androgen Deprivation Therapy for Prostate Cancer With Preexisting Osteoporosis

Completed · Phase 3

Conditions studied: Prostate Cancer

In brief

This study is being conducted to evaluate the effect of an investigational drug on bone loss in men with prostate cancer who are receiving Androgen Deprivation Therapy (ADT). In order to participate, male patients 18 years and older must be veterans from participating Veterans Administration Medical Centers that are receiving ADT for prostate cancer and have established osteoporosis.

Key facts

Study ID

NCT00171639

Run by

Novartis Pharmaceuticals

People needed

28

Starts

2004-06-01

Expected to finish

2007-03-01

Last updated by the study team

2017-02-23

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Signed informed consent
• Age > 18 years
• Histologically confirmed diagnosis of carcinoma of the prostate
• Stage M0: Patients just starting ADT must be stage M0 [PSA <10 (then bone scan not needed) or negative bone scan (regardless of PSA)]. Patients already on ADT must have been M0 at the initiation of ADT and have maintained a stable, low PSA (< 2.0) on continuous ADT since that time.
• Patients initiating or receiving ADT with a LHRH agonist (with or without an antiandrogen) and with the intended duration of ADT of at least 12 months from the time of randomization. Patients undergoing bilateral orchiectomy or with history of this procedure are also eligible. For patients already on ADT, the therapy must be continuous, and if there is more than one missed or delayed dose (> 1 mo delay) in any one year period, the patient is not eligible.
• Patient with a baseline BMD T-score <-2.0 in the lumbar spine (L2-L4) and/or the total hip are eligible
• Life expectancy of at least 12 months
• Zubrod performance status of 0, 1, or 2

You may not qualify if…

• Patients who received any bisphosphonate therapy in the past 6 months
• Metabolic bone disease including Paget's disease or hyperparathyroidism or vitamin D deficiency. Patients with vitamin D deficiency or secondary hyperparathyroidism due to vitamin D deficiency may be treated and reassessed for consideration for the trial, as detailed in Appendix 9.
• Radiographic evidence of bone metastases
• Patients who have received treatment with systemic corticosteroids within the past 12 months (short term corticosteroid therapy for up to one month duration, e.g. for acute illness like asthma exacerbation, is acceptable)
• Patients with prior exposure to anabolic steroids or growth hormone within the past 6 months
• Current treatment with estrogen or complementary medicines known to contain estrogens
• Patients with previous or concomitant malignancy within the past 5 years except adequately treated basal or squamous cell carcinoma of the skin, and colonic polyps with non-invasive malignancy which have been removed
• Patients with nonmalignant conditions which would confound the evaluation of the primary endpoint, impair tolerance of therapy, or prevent compliance to the protocol, including:
• uncontrolled infections
• uncontrolled type 2 diabetes mellitus
• diseases with influence on bone metabolism, such as Paget's disease or uncontrolled thyroid or parathyroid dysfunction
• cardiovascular, renal, hepatic, pulmonary and neurologic/psychiatric diseases which would prevent prolonged follow-up
• Patients with clinical or radiological evidence of existing fracture in the lumbar spine or either hip
• Patients with history of lumbar spine surgery that directly involved the bone or resulted in implanted hardware; or rendered the lumbar spine not evaluable (Some patients with a history of laminectomy alone may qualify).
• Patients with history of unilateral fracture of hip due to trauma or unilateral hip surgery and the other hip and lumbar spine are not evaluable.
• Patients for whom the lumbar spine and at least one hip are not evaluable for any reason.
• Patients treated with systemic investigational drugs(s) and /or device(s) within the past 30 days
• Patients with any prior treatment for osteoporosis except for calcium and vitamin D
• Patients with abnormal renal function as evidenced by either a serum creatinine greater than 3 mg/dL or by a calculated creatinine clearance of 40 ml/minute or less (Use Cockcroft-Gault equation. See Appendix 5).
• Corrected (adjusted for serum albumin) serum calcium concentration < 8.0 mg/dl (2.00 mmol/L)\\
• Other protocol-defined exclusion criteria may apply.

Where it is running

• Southern AZ VA Health Care System — Tucson, Arizona, United States
• VA Medical Center-Long Beach — Long Beach, California, United States
• Washington VA Medical Center — Washington D.C., District of Columbia, United States
• West Side VMAC — Chicago, Illinois, United States
• Hines VA Medical Center — Hines, Illinois, United States
• Kansas City VMAC — Kansas City, Missouri, United States
• VAWNY Buffalo — Buffalo, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.